{
    "ticker": "CHEB.WS",
    "name": "Chembio Diagnostics, Inc.",
    "description": "Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on developing and commercializing rapid diagnostic tests to improve patient outcomes. Founded in 1985, Chembio specializes in innovative and cost-effective testing solutions for infectious diseases, particularly in areas where access to laboratory facilities is limited. The company is recognized for its DPP\u00ae (Dual Path Platform) technology, which enables rapid and accurate testing for various diseases, including HIV, syphilis, and malaria. Chembio's tests are designed to be simple to use, providing results in as little as 15 minutes, which is crucial for timely diagnosis and treatment. The company's mission is to address unmet public health needs globally by providing accessible diagnostic solutions that enhance healthcare delivery. With a strong commitment to quality and regulatory compliance, Chembio works closely with health authorities and organizations to deploy its products in diverse settings, including hospitals, clinics, and remote healthcare facilities. Chembio is also actively engaged in research and development to expand its product portfolio and improve existing technologies, ensuring it remains at the forefront of the diagnostics industry.",
    "industry": [
        "Healthcare",
        "Medical Devices"
    ],
    "headquarters": "Hauppauge, New York, USA",
    "founded": "1985",
    "website": "https://www.chembio.com",
    "ceo": "John E. Bane",
    "social_media": {
        "twitter": "https://twitter.com/ChembioDx",
        "linkedin": "https://www.linkedin.com/company/chembio-diagnostics-inc/"
    },
    "investor_relations": "https://investors.chembio.com",
    "key_executives": [
        {
            "name": "John E. Bane",
            "position": "CEO"
        },
        {
            "name": "Richard D. W. McCulloch",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Tests",
            "products": [
                "DPP HIV 1/2 Test",
                "DPP Syphilis Screen",
                "DPP Malaria Test"
            ]
        }
    ],
    "seo": {
        "meta_title": "Chembio Diagnostics, Inc. | Rapid Diagnostic Testing Solutions",
        "meta_description": "Explore Chembio Diagnostics, Inc., a leader in rapid diagnostic tests for infectious diseases. Discover our innovative DPP technology and commitment to improving healthcare.",
        "keywords": [
            "Chembio",
            "Diagnostics",
            "Rapid Testing",
            "Infectious Diseases",
            "DPP Technology"
        ]
    },
    "faq": [
        {
            "question": "What does Chembio specialize in?",
            "answer": "Chembio specializes in rapid diagnostic tests for infectious diseases, utilizing innovative technologies."
        },
        {
            "question": "Where is Chembio headquartered?",
            "answer": "Chembio is headquartered in Hauppauge, New York, USA."
        },
        {
            "question": "What are some of Chembio's key products?",
            "answer": "Key products include the DPP HIV 1/2 Test, DPP Syphilis Screen, and DPP Malaria Test."
        },
        {
            "question": "When was Chembio founded?",
            "answer": "Chembio was founded in 1985."
        }
    ],
    "competitors": [
        "ABT",
        "BDX",
        "RMD",
        "DXCM"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GOOGL",
        "AMZN"
    ]
}